Benefits and limitations of plasmapheresis in renal diseases: An evidence-based approach

Journal of Artificial Organs

Volumn 14, Issue 1, 2011, Pages 9-22

  Baweja, Sanjeev ^a   Wiggins, Kate ^a   Lee, Darren ^a   Blair, Susan ^a   Fraenkel, Margaret ^a   McMahon, Lawrence P ^a  

^a EASTERN HEALTH   (Australia)

Author keywords

Plasmapheresis; Renal diseases; Renal failure; Renal transplantation

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FRESH FROZEN PLASMA; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; PROTEASOME INHIBITOR; RITUXIMAB; SHIGA TOXIN; STEROID; T LYMPHOCYTE ANTIBODY; TACROLIMUS; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANCA ASSOCIATED VASCULITIS; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; BLOOD GROUP ABO INCOMPATIBILITY; CANCER CHEMOTHERAPY; CLINICAL EFFECTIVENESS; CRYOGLOBULINEMIA; DRUG EFFICACY; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIS; HEMOLYTIC UREMIC SYNDROME; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MULTIPLE MYELOMA; PLASMA TRANSFUSION; PLASMAPHERESIS; PREECLAMPSIA; PRIORITY JOURNAL; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RECURRENT DISEASE; RENAL REPLACEMENT THERAPY; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THERAPY EFFECT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT INDICATION; VIRUS INFECTION; WALDENSTROEM MACROGLOBULINEMIA;

EVIDENCE-BASED MEDICINE; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; PLASMAPHERESIS; TREATMENT OUTCOME;

EID: 79955809922     PISSN: 14347229     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10047-010-0529-5     Document Type: Review

References (229)

1. Abel JJ, Rowntree LG, Turner BB. Plasma removal with return of corpuscles (plasmapheresis). J Pharmacol Exp Ther. 1914;5:625-41.
2. Schwab PJ, Fahey JL. Treatment of Waldenström's macroglobulinemia by plasmapheresis. N Engl J Med. 1960;263:574-9.
3. Rahman T, Harper L. Plasmapheresis in nephrology: an update. Curr Opin Nephrol Hypertens. 2006;15:603-9. (Pubitemid 44607432)
4. Low A, Hotze A, Krapf F, Schranz W, Manger BJ, Mahlstedt J, Wolf F, Kalden JR. The nonspecific clearance function of the reticuloendothelial system in patients with immune complex mediated diseases before and after therapeutic plasmapheresis. Rheumatol Int. 1985;5:69-72. (Pubitemid 15167145)
5. Bystryn JC, Graf MW, Uhr JW. Regulation of antibody formation by serum antibody. II. Removal of specific antibody by means of exchange transfusion. J Exp Med. 1970;132:1279-87.
6. Goto H, Matsuo H, Nakane S, Izumoto H, Fukudome T, Kambara C, Shibuya N. Plasmapheresis affects T helper type-1/T helper type-2 balance of circulating peripheral lymphocytes. Ther Apher. 2002;5:494-6. (Pubitemid 34037589)
7. Lockwood CM, Worlledge S, Nicholas A, Cotton C, Peters DK. Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange. N Engl J Med. 1979;300:524-30. (Pubitemid 9167826)
8. Siami GA, Siami FS. Plasmapheresis and paraproteinemia: cryoprotein-induced diseases, monoclonal gammopathy, Waldenström's macroglobulinemia, hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis. Ther Apher. 1999;3:8-19. (Pubitemid 29133865)
9. Wood L, Bond R, Jacobs P. Comparison of filtration to continuous- flow centrifugation for plasma exchange. J Clin Apher. 1984;2:155-62. (Pubitemid 14014590)
10. Opatrny K, Pittrova H, Opatrny K, Kovarikova P, Cerhova M, Rusnakova H. Comparison of the therapeutic effectiveness of membrane and centrifugation plasmapheresis. Vnitr Lek. 1990;36:978-84.
11. Madore F, Lazarus JM, Brady HR. Therapeutic plasma exchange in renal diseases. J Am Soc Nephrol. 1996;7:367-86. (Pubitemid 26128308)
12. Kaplan AA. Towards a rational prescription of plasma exchange: the kinetics of immunoglobulin removal. Semin Dial. 1992;5:227-9.
13. Kaplan AA. A simple and accurate method for prescribing plasma exchange. Am Soc Artif Intern Organs Trans. 1990;36: M597-9.
14. Roberts CG, Schindhelm K, Smeby LC, Farrell PC. Kinetic analysis of plasma separation: use of an animal model. In: Lysaght MJ, Gurland HJ, editors. Plasma separation and plasma fractionation. Basel: Karger; 1983. p. 25-38.
15. Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis. 1994;23:817-27. (Pubitemid 24173565)
16. Sutton DM, Nair RC, Rock G. Complications of plasma exchange. Transfusion. 1989;29:124-7. (Pubitemid 19137856)
17. Norda R, Stegmayr BG. Apheresis registry in Sweden: scope, techniques and indications for treatment. A report from the Swedish apheresis study group. Transfus Apher Sci. 2001;24:49-55.
18. Pohl MA, Lan SP, Berl T. Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. Ann Intern Med. 1991;114:924-9.
19. Owen HG, Brecher ME. Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis. Transfusion. 1994;34:891-4. (Pubitemid 24308112)
20. Szczepiorkowski ZM, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2007;22:106-75. (Pubitemid 47025120)
21. Strauss RG, Ciavarella D, Gilcher RO, Kasprisin DO, Kiprov DD, Klein HG, McLeod BC. An overview of current management. J Clin Apher. 1993;8:189-94. (Pubitemid 23360775)
22. Leitman SF, Ciavarella D, McLeod B, Owen H, Price T, Sniecinski I. Guidelines for therapeutic hemapheresis. Bethesda: American Association of Blood Banks; 1994.
23. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment of plasmapheresis. Neurology. 1996;47:840-3.
24. Bolton WK. Nephrology forum: Goodpasture's syndrome. Kidney Int. 1996;50:1753-66.
25. Saus J, Wieslander J, Langeveld JP, Quinones S, Hudson BG. Identification of the Goodpasture antigen as the alpha 3(IV) chain of collagen IV. J Biol Chem. 1988;263:13374-80.
26. Lockwood CM, Boulton-Jones JM, Lowenthal RM, Simpson IJ, Peters DK. Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis. Br Med J. 1975;2:252-4.
27. Benoit FL, Rulon DB, Theil GB, Doolan PD, Wattern RH. Goodpasture's syndrome: a clinicopathologic entity. Am J Med. 1964;37:424-44.
28. Proskey AJ, Weatherbee L, Easterling RE, Greene JA Jr, Weller JM. Goodpasture's syndrome: a report of five cases and review of the literature. Am J Med. 1970;48:162-73.
29. Wilson CB, Dixon FJ. Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int. 1973;3:74-89.
30. Bouget J, Le Pogamp P, Perrier G, Ramee MP, Rivalan J, Camus C, Thomas R, Chevet D. Anti-basement-membrane antibody mediated, rapidly progressive, glomerulonephritis. Diagnostic and therapeutic strategy based on a retrospective study of 14 cases. Ann Med Intern (Paris). 1990;141:409-15.
31. Herody M, Bobrie G, Gouarin C, Grünfeld JP, Noel LH. Anti- GBM disease: predictive value of clinical, histological and serological data. Clin Nephrol. 1993;40:249-55. (Pubitemid 23333355)
32. Merkel F, Pullig O, Marx M, Netzer KO, Weber M. Course and prognosis of anti-basement membrane antibody (anti-BM-Ab)-mediated disease: report of 35 cases.Nephrol Dial Transpl. 1994;9:372-6.
33. Andrews PA, Sheerin NS, Hicks JA, Williams DG, Sacks SH. Unusual presentations of anti-glomerular basement membrane antibody mediated disease are associated with delayed diagnosis and poor outcome. Clin Nephrol. 1995;44:262-5.
34. Daly C, Conlon PJ, Medwar W, Walshe JJ. Characteristics and outcome of anti-glomerular basement membrane disease: a single-center experience. Ren Fail. 1996;18:105-12. (Pubitemid 26073879)
35. Saurina A, Arrizabalaga P, Rodriguez R, Poveda R, Valles M, Pou M, Mirapeix E. Anti-glomerular basement membrane antibody mediated disease: revision of 32 cases and follow-up at one year of the diagnosis. Nefrologia. 2003;23:415-22. (Pubitemid 39233232)
36. Simpson IJ, Doak PB, Williams LC, Blacklock HA, Hill RS, Teague CA, Herdson PB, Wilson CB. Plasma exchange in Goodpasture's syndrome. Am J Nephrol. 1982;2:301-11. (Pubitemid 13181772)
37. Johnson JP, Moore J Jr, Austin HA 3rd, Balow JE, Antonovych TT, Wilson CB. Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore). 1985;64:219-27. (Pubitemid 16247105)
38. Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001;134:1033-42. (Pubitemid 32488657)
39. Couser WG. Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis. 1988;11:449-64.
40. Jennette JC, Falk RJ. The pathology of vasculitis involving the kidney. Am J Kidney Dis. 1994;24:130-41. (Pubitemid 24212988)
41. Kallenberg CG, Brouwer E, Weening JJ, Tervaert JW. Antineutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int. 1994;46:1-15. (Pubitemid 24210431)
42. Watts RA, Scott DG. Epidemiology of the vasculitides. Curr Opin Rheumatol. 2003;15:11-6. (Pubitemid 36021018)
43. Hagen E, Daha M, Hermans J, Andrassy K, Csernok E, Gaskin G, Lesavre P, Lüdemann J, Rasmussen N, Sinico RA, Wiik A, van der Woude FJ. Diagnostic value of standardised assays for antineutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int. 1998;53:743-53. (Pubitemid 28124291)
44. Ewert BH, Jennette JC, Falk RJ. Anti-myeboperoxldase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int. 1992;41:375-83.
45. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA. 1990;87:4114-9.
46. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ, Jennette JC. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110:955-63.
47. Huugen D, Xiao H, van Esch A, Falk RJ, Peutz-Kootstra CJ, Buurman WA, Tervaert JW, Jennette JC, Heeringa P. Aggravation of antimyeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol. 2005;167:47-58. (Pubitemid 40884769)
48. Little MA, Smyth CL, Yadav R, Ambrose L, Cook HT, Nourshargh S, Pusey CD. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood. 2005;106:2050-8. (Pubitemid 41291719)
49. Pettersson EE, Sundelin B, Heigl Z. Incidence and outcome of pauci-immune necrotizing and crescentic lomerulonephritis in adults. Clin Nephrol. 1995;43:141-9.
50. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C, European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36-44. (Pubitemid 36765101)
51. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116:488-98.
52. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221-32.
53. Jones RB, Tervaert JWC, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR, European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211-20.
54. Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, Plaisance M, Pusey CD, Jayne DR, Pan-Thames Renal Research Group. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003;41:776-84. (Pubitemid 36396745)
55. Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol. 1998;9:842-52. (Pubitemid 28209094)
56. Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int. 1991;40:757-63.
57. Cole E, Cattran D, Magil A, Greenwood C, Churchill D, Sutton D, Clark W, Morrin P, Posen G, Bernstein K. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am J Kidney Dis. 1992;20:261-9.
58. Guillevin L, Lhote F, Cohen P, Jarrousse B, Lortholary O, Genereau T, Leon A, Bussel A. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum. 1995;38:1638-45.
59. Zauner I, Bach D, Braun N, Kramer BK, Funfstuck R, Helmchen U, Schollmeyer P, Bohler J. Predictive value of initial histology and effect of plasmapheresis on long-term prognosis of rapidly progressive glomerulonephritis. Am J Kidney Dis. 2002;39:28-35. (Pubitemid 34062492)
60. Lockwood CM, Pinching AJ, Sweny P, Rees AJ, Pussell B, Uff J, Peters DK. Plasma-exchange and immunosuppression in the treatment of fulminating immune-complex crescentic nephritis. Lancet. 1977;1:63-7. (Pubitemid 8013799)
61. van Wijngaarden RA, Hauer HA, Wolterbeek R, Jayne DR, Gaskin G, Rasmussen N, Noël LH, Ferrario F, Waldherr R, Hagen EC, Bruijn JA, Bajema IM. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol. 2006;17:2264-74. (Pubitemid 44141917)
62. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, Westman KW, van der Woude FJ, de Lind van Wijngaarden RA, Pusey CD, European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18:2180-8. (Pubitemid 47041083)
63. Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, Amouroux J, Casassus P, Jarrousse B. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999;42:421-30. (Pubitemid 29136088)
64. Gallagher H, Kwan JT, Jayne DR. Pulmonary renal syndrome: A 4-year, single-center experience. Am J Kidney Dis. 2002;39:42-7. (Pubitemid 34062494)
65. Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis. 2003;42:1149-53. (Pubitemid 37486757)
66. Iwatani H, Uzu T, Kakihara M, Nakayama Y, Kanasaki K, Yamato M, Hirai Y, Umimoto K, Yamauchi A. A case of Wegener's granulomatosis with pulmonary bleeding successfully treated with double filtration plasmapheresis (DFPP). Clin Exp Nephrol. 2004;8:369-74. (Pubitemid 40941116)
67. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589-600.
68. Scheiring J, Rosales A, Zimmerhackl LB. Today's understanding of the hemolytic uraemic syndrome. Eur J Pediatr. 2010;169:7-13.
69. Moake J. Thrombotic thrombocytopenia purpura (TTP) and other thrombotic microangiopathies. Best Pract Res Clin Haematol. 2009;22:567-76.
70. Byrnes JJ, Moake JL. Thrombotic thrombocytopenic purpura and the hemolytic-uraemia syndrome: evolving concept of pathogenesis and therapy. Clin Haematol. 1986;15:413-42. (Pubitemid 16028879)
71. Remuzzi G. HUS and TTP: variable expression of a single entity. Kidney Int. 1987;32:292-308. (Pubitemid 17122985)
72. Shepard KV, Bukowski RM. The treatment of thrombotic thrombocytopenic purpura with exchange transfusions, plasma infusions, and plasma exchange. Semin Hematol. 1987;24:178-93.
73. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488-94. (Pubitemid 32938741)
74. Ruiz-Torres MP, Casiraghi F, Galbusera M, Macconi D, Gastoldi S, Todeschini M, Porrati F, Belotti D, Pogliani EM, Noris M, Remuzzi G. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost. 2005;93:443-52. (Pubitemid 40392531)
75. Bernardo A, Ball C, Nolasco L, Choi H, Moake JL, Dong JF. Platelets adhered to endothelial cellbound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress. J Thromb Haemost. 2005;3:562-70. (Pubitemid 41632882)
76. Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A, Gerstenbauer G, Konetschny C, Zimmermann K, Scharrer I, Peyvandi F, Galbusera M, Remuzzi G, Bohm M, Plaimauer B, Lammle B, Scheiflinger F. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005;106:1262-7. (Pubitemid 41129589)
77. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103:4043-9. (Pubitemid 38685342)
78. Sadler JE. Thrombotic thrombocytopenic purpura: a moving target. Hematol Am Soc Hematol Educ Program. 2006;415-20.
79. Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematol Am Soc Hematol Educ Program. 2004;407-23.
80. Bukowski RM, King JW, Hewlett JS. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood. 1977;50:413-7. (Pubitemid 8180423)
81. Byrnes JJ, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med. 1977;297:1386-9. (Pubitemid 8256298)
82. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore). 1966;45:139-59.
83. Forzley BR, Sontrop JM, Macnab JJ, Chen S, Clark WF. Treating TTP/HUS with plasma exchange: a single centre's 25- year experience. Br J Haematol. 2008;143:100-6.
84. Lacone A, Dragani A. Di 0G. Thrombotic thrombocytopenlc purpura (TTP) treatment: Italian cooperative retrospective study on 29 cases. Haematologica. 1986;71:39-43.
85. Bell WR, Braine WG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med. 1991;325:398-403.
86. French Cooperative Study Group for Adult HUS. Adult hemolytic uremic syndrome with renal microangiopathy. Outcome according to therapeutic protocol in 53 cases. Ann Med Intern. 1992;43:27-32.
87. Dundas S, Murphy J, Soutar RL, Jones GA, Hutchinson SJ, Todd WT. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak. Lancet. 1999;354:1327-30.
88. Michael M, Elliott EJ, Ridley GF, Hodson EM, Craig JC. Interventions for hemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database Syst Rev. 2009 (1): CD003595. doi:10.1002/14651858.CD003595.pub2.
89. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325:393-7.
90. Henon P. Thrombotic thrombocytopenic purpura: clinical results of a French controlled trial. Transfus Sci. 1992;13:63-72.
91. Bobbio-Pallavicini E, Gugliotta L, Centurioni R, Porta C, Vianelli N, Billio A, Tacconi F, Ascari E. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica. 1997;82:429-35.
92. Zeigler ZR, Shadduck RK, Gryn JF, Rintels PB, George JN, Besa EC, Bodensteiner D, Silver B, Kramer RE, North American TTP Group. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apher. 2001;16:19-22. (Pubitemid 32374499)
93. Rothele E, Krumme B, Rump LC. Design of the prospective randomized study for the treatment of patients with thrombotic microangiopathy. PRODROMI Study Group. Ther Apher. 2000;4:327-31.
94. Rock G, Anderson D, Clark W, Leblond P, Palmer D, Sternbach M, Sutton D, Wells G, Canadian Apheresis Group. Canadian Association of Apheresis Nurses. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol. 2005;129:79-86. (Pubitemid 40524055)
95. Ziman A, Mitri M, Klapper E, Pepkowitz SH, Goldfinger D. Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution's experience and review of the literature. Transfusion. 2005;45:41-9.
96. Lammle B, Kremer Hovinga JA, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost. 2005;3:1663-75. (Pubitemid 41716552)
97. Rock GA. Management of thrombotic thrombocytopenic purpura. Br J Haematol. 2000;109:496-507. (Pubitemid 30415172)
98. Vitacco M, Sanchez Avalos J, Gianantonio CA. Heparin therapy in the hemolytic uremic syndrome. J Pediatr. 1973;83:271-5.
99. Perez N, Spizzirri F, Rahman R, Suarez A, Larrubia C, Lasarte P. Steroids in the hemolytic uremic syndrome. Pediatr Nephrol. 1998;12:101-4. (Pubitemid 28165795)
100. Rizzoni G, Claris-Appiani A, Edefonti A, Facchin P, Franchini F, Gusmano R, Imbasciati E, Pavanello L, Perfumo F, Remuzzi G. Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr. 1988;112:284-90. (Pubitemid 18093822)
101. Loirat C, Beaufils E, Sonsino N, Schlegel M, Guesnu G, Pillon G, Andre JL, Broyer M, Guyot C, Habib R. Treatment of childhood hemolytic-uremic syndrome with urokinase. Cooperative controlled trial. Arch Fr Pediatr. 1984;41:15-9.
102. Loriat C, Sonsino E, Hinglais N, Jais JP, Landais P, Fermanian J. Treatment of the childhood hemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr Nephrol. 1988;2:279-85.
103. Van Damme-Lombaerts R, Proesmans W, Van Damme B, Eeckels R, Binda ki Muaka P, Mercieca V, Vlietinck R, Vermylen J. Heparin plus dipyridamole in childhood hemolyticuremic syndrome: a prospective, randomized study. J Pediatr. 1988;113:913-8.
104. Trachtman H, Cnaan A, Christen E, Gibbs K, Zhao S, Acheson DW, Weiss R, Kaskel FJ, Spitzer A, Hirschman GH, Investigators of the HUS-SYNSORB Pk Multicenter Clinical Trial. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA. 2003;290:1337-44.
105. Pereira A, Mazzara R, Monteagudo J, Sanz C, Puig L, Martinez A, Ordinas A, Castillo R. Thrombotic thrombocytopenic purpura/ hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Ann Hematol. 1995;70:319-23.
106. Fontana S, Kremer Hovinga JA, Lammle B, Mansouri Taleghani B. Treatment of thrombotic thrombocytopenic purpura. Vox Sang. 2006;90:245-54.
107. Charles ED, Dustin LB. Hepatitis C virus-induced cryoglobulinemia. Kidney Int. 2009;76:818-24.
108. Frankel AR, Singer DR, Winearis CG, Evans DJ, Rees AJ, Pusey CD. Type II essential mixed cryoglobulinaemia: presentation, treatment and outcome in 13 patients. Q J Med. 1992;82:101-24.
109. Tarantino A, de Vecchi A, Montaguino G, Imbasciati E, Mihatsch MJ, Zollinger HU, Di Belgiojoso GB, Busnach G, Ponticelli C. Renal disease in essential mixed cryoglobulinemia: long-term follow-up of 44 patients. Q J Med. 1981;50:1-30. (Pubitemid 11099592)
110. Berkman EM, Orlin JB. Use of plasmapheresis and partial plasma exchange in the management of patients with cryoglobulinemla. Transfusion. 1980;20:171-8. (Pubitemid 10086629)
111. Auzerie V, Chiali A, Bussel A, Brouet JC, Fermand JP, Dubertret L, Senet P. Leg ulcers associated with cryoglobulinemia: clinical study of 15 patients and response to treatment. Arch Dermatol. 2003;139:391-3. (Pubitemid 36330599)
112. Monti G, Saccardo F. Emergency in cryoglobulinemic syndrome: what to do? Dig Liver Dis. 2007;39(Suppl 1):S112-5.
113. Dominguez JH, Sha E. Apheresis in cryoglobulinemia complicating hepatitis C and in other renal diseases. Ther Apher. 2002;6:69-76. (Pubitemid 34218730)
114. Galli M, Monti G, Invernizzi F, Invernizzi F, Monteverde A, Bombardieri S, Gabrielli A, Migliaresi S, Mussini C, Ossi E, Pietrogrande M. Hepatitis B virus-related markers in secondary and essential mixed cryoglobulinemias: a multicenter study of 596 cases. The Italian Group for the Study of Cryoglobulinemias (GISC). Ann Ital Med Int. 1992;7:209-14. (Pubitemid 23051883)
115. Sinico RA, Fornasieri A, Fiorini G, Paracchini ML, Renoldi P, Maldifassi P, Bucci A, Ferrario F, D'Amico G. Plasma exchange in the treatment of essential mixed cryoglobulinemla nephropathy. Long-term follow up. Int J Artif Organs. 1985;2:15-8. (Pubitemid 16209356)
116. Valbonesi M, Montani F, Mosconi L, Florio G, Vecchi C. Plasmapheresis and cytotoxic drugs for mixed cryoglobulinemia. Haematologia (Budapest). 1984;17:341-51. (Pubitemid 14046698)
117. L'Abbate A, Maggiore Q', Caccamo A, Misefari V, Bartolomeo F, Delfino D, Cutrupi S, Pagnotta G. Long term effects of cryoapheresis and cytostatic treatment in essential mixed cryoglobulinemia. Int J Artif Organs. 1985;2:19-22. (Pubitemid 16209357)
118. Schena FP, Manno C, Dimonte D, Carabellese S, Cazzato L, Paglionico N, Russo R. Plasma exchange in the treatment of cryoglobulinemia. Ric Clin Lab. 1983;13:133-40.
119. Ferri C, Moriconi L, Gremignal G, Migliorini P, Paleologo G, Fosella PV, Bombardieri S. Treatment of the renal involvement in mixed cryoglobulinemia with prolonged plasma exchange. Nephron. 1986;43:246-53. (Pubitemid 16093337)
120. Ramunni A, Lauletta G, Brescia P, Saliani MT, Montrone M, Chironna M, Sansonno D, Dammacco F, Coratelli P. Doublefiltration plasmapheresis in the treatment of leg ulcers in cryoglobulinemia. J Clin Apher. 2008;23:118-22.
121. Stefanutti C, Vivenzio A, Di Giacomo S, Labbadia G, Mazza F, D'Alessandri G, Ferraro PM, Masala C. Immunoadsorption apheresis and immunosuppressive drug therapy in the treatment of complicated HCV-related cryoglobulinemia. J Clin Apher. 2009;24:241-6.
122. Siami GA, Siami FS. Current topics on cryofiltration technologies. Ther Apher. 2001;5:283-6. (Pubitemid 33062676)
123. De Vita S, Quartuccio L. Rituximab monotherapy, rather than rituximab plus antiviral drugs, for initial treatment of severe HCV-related mixed cryoglobulinemia syndrome. Arthritis Rheum. 2010;62:908-9.
124. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975;50:29-40.
125. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med. 1990;150:1693-5.
126. Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S, Cases A, Darnell A, Rozman C, Montserrat E. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158:1889-93. (Pubitemid 28440861)
127. Sakhuja V, Jha V, Varma S, Joshi K, Gupta KL, Sud K, Kohli HS. Renal involvement in multiple myeloma: a 10-year study. Ren Fail. 2000;22:465-77. (Pubitemid 30441642)
128. DeFronzo RA, Cooke CR, Wright JR, Humphrey RL. Renal function in patients with multiple myeloma. Medicine (Baltimore). 1978;57:151-66. (Pubitemid 8340559)
129. Fang LST. Light chain nephropathy. Kidney Int. 1985;27:582-92. (Pubitemid 15076767)
130. Herrera GA. Renal manifestations of plasma cell dyscrasias: an appraisal from the patients' bedside to the research laboratory. Ann Diagn Pathol. 2000;4:174-200. (Pubitemid 30480217)
131. Ivanyi B. Frequency of light chain deposition nephropathy relative to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma. Arch Pathol Lab Med. 1990;114:986-7. (Pubitemid 20265301)
132. Montseny JJ, Kleinknecht D, Meyrier A, Vanhille P, Simon P, Pruna A, Eladari D. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transpl. 1998;13:1438-45. (Pubitemid 28254318)
133. Abbott KC, Agodoa LY. Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol. 2001;56:207-10. (Pubitemid 32827556)
134. Pozzi C, Pasquali S, Donini U, Casanova S, Banfi G, Tiraboschi G, Furci L, Porri MT, Ravelli M, Lupo A. Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: a review of 50 cases. Report of the Italian Renal Immunopathology Group. Clin Nephrol. 1987;28:1-9.
135. Feest TG, Burge PS, Cohen SL. Successful treatment of myeloma kidney by diuresis and plasmaphoresis. Br Med J. 1976;28: 503-4.
136. Wahlin A, Lofvenberg E, Holm J. Improved survival in multiple myeloma with renal failure. Acta Med Scand. 1987;221:205-9. (Pubitemid 17072881)
137. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int. 1988;33:1175-80.
138. Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med. 1990;150:863-9.
139. Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, Heidenheim AP, Garg AX, Churchill DN, Canadian Apheresis Group. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005;143:777-84.
140. Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, Kumar S, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Hayman SR, Russell SJ, Kyle RA, Winters JL. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 2008;73:1282-8. (Pubitemid 351693147)
141. Hutchison CA, Cockwell P, Reid P, Chandler P, Mead GP, Harrison J, Hattersley J, Evans ND, Chappell MJ, Cook M, Goehl H, Storr M, Bradwell AR. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol. 2007;18:886-95. (Pubitemid 46434505)
142. Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S, Hattersley J, Evans ND, Chappel MJ, Sampson P, Foggensteiner L, Adu D, Cockwell P. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol. 2009;4:745-54.
143. Hutchison CA, Cook M, Heyne N, Weisel K, Billingham L, Bradwell A, Cockwell P. European trial of free light chain removal by extended hemodialysis in cast nephropathy (Eu- LITE): a randomised control trial. Trials. 2008;9:55.
144. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, Morra E, Pangalis GA, San Miguel JF, Branagan AR, Dimopoulos MA. Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the second international workshop on Waldenström's macroglobulinemia. Semin Oncol. 2003;30:110-5. (Pubitemid 36506291)
145. Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole DH, Gertz MA, Eastern Cooperative Oncology Group. Initial immunoglobulin M "flare" after rituximab therapy in patients with Waldenström macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004;101:2593-8.
146. Menke MN, Treon SP. Hyperviscosity syndrome. In: Sekeres MA, Kalaycio ME, Bolwell BJ, editors. Clinical malignant hematology. New York: McGraw-Hill; 2007. p. 937-41.
147. Fonseca R, Hayman S. Waldenström macroglobulinaemia. Br J Haematol. 2007;138:700-20.
148. Nelson PW, Landreneau MD, Luger AM GE, Ross G, Shield CF 3rd, Warady BA, Aeder MI, Helling TS, Hughes TM, Beck ML, Harrell KM, Bryan CF. Ten-year experience in transplantation of A2 kidneys into B and O recipients. Transplantation. 1998;65:256-60. (Pubitemid 28099221)
149. Sorensen JB, Grant WJ, Belnap LP, Stinson J, Fuller TC. Transplantation of ABO group A2 kidneys from living donors into group O and B recipients. Am J Transpl. 2001;1:296-9. (Pubitemid 33674176)
150. Alkhunaizi AH, De Mattos AM, Barry JM, Bennett WM, Norman DJ. Renal transplantation across the ABO barrier using A2 kidneys. Transplantation. 1999;67:1319-24. (Pubitemid 29252406)
151. Bryan CF, Nelson PW, Shield CF 3rd, Ross G, Warady B, Murillo D, Winklhofer FT. Transplantation of A2 and A2B kidneys from deceased donors into B waiting list candidates increases their transplantation rate. Clin Transpl 2004;127-33.
152. Futagawa Y, Terasaki PI. ABO incompatible kidney transplantation: an analysis of UNOS registry data. Clin Transpl. 2006;20:122-6. (Pubitemid 43349037)
153. Gloor JM, Lager DJ, Moore SB, Pineda AA, Fidler ME, Larson TS, Grande JP, Schwab TR, Griffin MD, Prieto M, Nyberg SL, Velosa JA, Textor SC, Platt JL, Stegall MD. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation. 2003;75:971-7. (Pubitemid 36438524)
154. Tanabe K, Takahashi K, Sonda K, Tokumoto T, Ishikawa N, Kawai T, Fuchinoue S, Oshima T, Yagisawa T, Nakazawa H, Goya N, Koga S, Kawaguchi H, Ito K, Toma H, Agishi T, Ota K. Long-term results of ABO incompatible living kidney transplantation. Transplantation. 1998;65:224-8. (Pubitemid 28101328)
155. Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation. 2002;74:1207-10. (Pubitemid 35402585)
156. Takahashi K, Saito K, Takahara S, Okuyama A, Tanabe K, Toma H, Uchida K, Hasegawa A, Yoshimura N, Kamiryo Y, Japanese ABO-Incompatible Kidney Transplantation Committee. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transpl. 2004;4:1089-96. (Pubitemid 38868599)
157. Gloor JM, Lager DJ, Fidler ME, Grande JP, Moore SB, Winters JL, Kremers WK, Stegall MD. A comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation. 2005;80:1572-7. (Pubitemid 43005868)
158. Sonnenday CJ, Warren DS, Cooper M, Samaniego M, Haas M, King KE, Shirey RS, Simpkins CE, Montgomery RA. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transpl. 2004;4:1315-22. (Pubitemid 39013579)
159. Ichimaru N, Takahara S. Japan's experience with living-donor kidney transplantation across ABO barriers. Nat Clin Pract Nephrol. 2008;4:682-92.
160. Tyden G, Donauer J, Wadstrom J, Kumlien G, Wilpert J, Nilsson T, Genberg H, Pisarski P, Tufveson G. Implementation of a protocol for ABO-incompatible kidney transplantation - a three-center experience with 60 consecutive transplantations. Transplantation. 2007;83:1153-5. (Pubitemid 46743673)
161. Tyden G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transpl. 2005;5:145-8. (Pubitemid 40095139)
162. Tyden G, Kumlien G, Efvergren M. Present techniques for antibody removal. Transplantation. 2007;84:S27-9.
163. Kumlien G, Ullström L, Losvall A, Persson LG, Tyden G. Clinical experience with a new apheresis filter that specifically depletes ABO blood group antibodies. Transfusion. 2006;46:1568-75. (Pubitemid 44326333)
164. Friedrich Thaiss. Specific issues in living donor kidney transplantation: ABO-incompatibility. Atheroscler Suppl. 2009;10:133-6.
165. Ishida H, Tanabe K, Ishizuka T, Furusawa M, Miyamoto N, Ishikawa N, Shirakawa H, Shimmura H, Ishii D, Nozaki T, Setoguchi K, Toma H. The mechanism responsible for accommodation after living-related kidney transplantations across the blood barrier. Transpl Int. 2005;18:716-20. (Pubitemid 41726838)
166. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transpl. 2003;3:1488-500. (Pubitemid 37541506)
167. Gloor JM, DeGoey SR, Pineda AA, Moore SB, Prieto M, Nyberg SL, Larson TS, Griffin MD, Textor SC, Velosa JA, Schwab TR, Fix LA, Stegall MD. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transpl. 2003;3:1017-23. (Pubitemid 36917550)
168. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transpl. 2004;8:535-42. (Pubitemid 40052349)
169. Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, Maley WR, Ratner LE. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match positive recipients. Transplantation. 2000;70:887-95.
170. Schweitzer EJ, Wilson JS, Fernandez-Vina M, Fox M, Gutierrez M, Wiland A, Hunter J, Farney A, Philosophe B, Colonna J, Jarrell BE, Bartlett ST. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation. 2000;70:1531-6.
171. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transpl. 2006;6:346-51. (Pubitemid 43382170)
172. Thielke JJ, West-Thielke PM, Herren HL, Bareato U, Ommert T, Vidanovic V, Campbell-Lee SA, Tzvetanov IG, Sankary HN, Kaplan B, Benedetti E, Oberholzer J. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation. 2009;87:268-73.
173. Glotz D, Antoine C, Julia P, Suberbielle-Boissel C, Boudjeltia S, Fraoui R, Hacen C, Duboust A, Bariety J. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transpl. 2002;2:758-60. (Pubitemid 36342618)
174. Jordan SC, Vo AA, Nast CC, Tyan D. Use of high-dose human intravenous immunoglobulin therapy in sensitized patients awaiting transplantation: the Cedars-Sinai experience. Clin Transpl. 2003;193-8.
175. Higgins RM, Bevan DJ, Carey BS, Lea CK, Fallon M, Bühler R, Vaughan RW, O'Donnell PJ, Snowden SA, Bewick M, Hendry BM. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet. 1996;348:1208-11. (Pubitemid 26361608)
176. Lorenz M, Regele H, Schillinger M, Kletzmayr J, Haidbauer B, Derfler K, Druml W, Böhmig GA. Peritransplant immunoadsorption: a strategy enabling transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients. Transplantation. 2005;79:696-701. (Pubitemid 40463176)
177. Yin H, Hu XP, Li XB, Liu H, Wang W, Ren L, Wang Y, Zhang XD. Protein A immunoadsorption combined with rituximab in highly sensitized kidney transplant recipients. Chin Med J (England). 2009;122:2752-6.
178. Vo AA, Peng A, Toyoda M, Kahwaji J, Cao K, Lai CH, Reinsmoen NL, Villicana R, Jordan SC. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation. 2010;89:1095-102.
179. Singh N, Pirsch J, Samaniego M. Antibody-mediated rejection: treatment alternatives and outcomes. Transpl Rev (Orlando). 2009;23:34-46.
180. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, Cecka MJ, Cosyns JP, Demetris AJ, Fishbein MC, Fogo A, Furness P, Gibson IW, Glotz D, Hayry P, Hunsickern L, Kashgarian M, Kerman R, Magil AJ, Montgomery R, Morozumi K, Nickeleit V, Randhawa P, Regele H, Seron D, Seshan S, Sund S, Trpkov K. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transpl. 2003;3:708-14. (Pubitemid 36745243)
181. Colvin R. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol. 2007;18:1046-56. (Pubitemid 46536891)
182. Bohming G, Regele H. Diagnosis and treatment of antibody mediated kidney allograft rejection. Transpl Int. 2003;16:773-87. (Pubitemid 37509413)
183. Ibernon M, Gil-Vernet S, Carrera M, Seron D, Moreso F, Bestard O, Cruzado JM, Grinyo JM. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation. Transpl Proc. 2005;37:3743-5.
184. Min L, Shuming J, Zheng T, Daxi J, Huiping C, Zhihong L, Leishi L. Novel rescue therapy for C4d-positive acute humoral renal allograft rejection. Clin Transpl. 2005;19:51-5. (Pubitemid 40227852)
185. Faguer S, Kamar N, Guilbeaud-Frugier C, Fort M, Modesto A, Mari A, Ribes D, Cointault O, Lavayssiere L, Guitard J, Durand D, Rostaing L. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation. 2007;83:1277-80. (Pubitemid 46743692)
186. White NB, Greenstein SM, Cantafio AW, Schechner R, Glicklich D, McDonough P, Pullman J, Mohandas K, Boctor F, Uehlinger J, Tellis V. Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation. 2004;78:772-4. (Pubitemid 39244747)
187. Bohmig GA, Wahrmann M, Regele H, Exner M, Robl B, Derfler K, Soliman T, Bauer P, Müllner M, Druml W. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transpl. 2007;7:117-21. (Pubitemid 44952863)
188. Walsh RC, Everly JJ, Brailey P, Rike AH, Arend LJ, Mogilishetty G, Govil A, Roy-Chaudhury P, Alloway RR, Woodle ES. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation. 2010;89:277-84.
189. Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, Hill GS, Glotz D, Suberbielle-Boissel C. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus highdose IVIg in the treatment of antibody-mediated rejection. Am J Transpl. 2009;9:1099-107.
190. Lehrich RW, Rocha PN, Reinsmoen N, Greenberg A, Butterly DW, Howell DN, Smith SR. Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: experience in renal allograft transplantation. Hum Immunol. 2005;66:350-8. (Pubitemid 40615789)
191. Pascual M, Saidman S, Tolkoff-Rubin N, Williams WW, Mauiyyedi S, Duan JM, Farrell ML, Colvin RB, Cosimi AB, Delmonico FL. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation. 1998;66:1460-4. (Pubitemid 29014024)
192. Rocha PN, Butterly DW, Greenberg A, Reddan DN, Tuttle- Newhall J, Collins BH, Kuo PC, Reinsmoen N, Fields T, Howell DN, Smith SR. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation. 2003;75:1490-5. (Pubitemid 36597283)
193. Brown CM, Abraham KA, O'Kelly P, Conlon PJ, Walshe JJ. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation. Transpl Proc. 2009;41(9):3690-2.
194. Newstead CG. Recurrent disease in renal transplants. Nephrol Dial Transpl. 2003;18(Suppl 6):vi68-74.
195. Weber S, Tonshoff B. Recurrence of focal-segmental glomerulosclerosis in children after renal transplantation: clinical and genetic aspects. Transplantation. 2005;80:S128-34.
196. Briggs JD, Jones E. Recurrence of glomerulonephritis following renal transplantation. Nephrol Dial Transpl. 1999;14:564-5. (Pubitemid 29105978)
197. Hubsch H, Montane B, Abitobol C, Chandar J, Shariatmadar S, Ciancio G, Burke G, Miller J, Strauss J, Zilleruelo G. Recurrent focal glomerulosclerosis in pediatric renal allografts: the Miami experience. Pediatr Nephrol. 2005;20:210-6. (Pubitemid 40174037)
198. Nathanson S, Cochat P, Andre JL, Guyot C, Loirat C, Nivet H, Deschenes G. Recurrence of nephrotic syndrome after renal transplantation: influence of increased immunosuppression. Pediatr Nephrol. 2005;20:1801-4. (Pubitemid 41722968)
199. Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M, Vincenti F. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med. 1996;334:878-83. (Pubitemid 26107345)
200. Dantal J, Testa A, Bigot E, Soulillou JP. Disappearance of proteinuria after immunoadsorption in a patient with focal glomerulosclerosis. Lancet. 1990;336:190. (Pubitemid 20225034)
201. Feld S, Figueroa P, Savin V, Nast CC, Sharma R, Sharma M, Hirschberg R, Adler SG. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis. Am J Kidney Dis. 1998;32:230-7.
202. Artero M, Biava C, Amord W, Tomlanovich S, Vincenti F. Recurrent focal glomerulosclerosis: natural history and response to therapy. Am J Med. 1992;92:375-83.
203. Shariatmadar S, Noto TA. Therapeutic plasma exchange in recurrent focal segmental glomerulosclerosis following transplantation. J Clin Apher. 2002;17:78-83. (Pubitemid 34809555)
204. Pradhan M, Petro J, Palmer J, Meyers K, Baluarte HJ. Early use of plasmapheresis for recurrent post transplant FSGS. Pediatr Nephrol. 2003;18:934-8. (Pubitemid 37121629)
205. Valdivia P, Gonzalez Roncero F, Gentil MA, Jiménez F, Algarra G, Pereira P, Rivera M, Suñer M, Cabello V, Toro J, Mateos J. Plasmapheresis for the prophylaxis and treatment of recurrent focal segmental glomerulosclerosis following renal transplant. Transpl Proc. 2005;37:1473-4.
206. Deegens JKJ, Andresdotter MB, Croockewit S, Wetzels JF. Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplant. Transpl Int. 2004;17:151-7. (Pubitemid 38660692)
207. Cochat P, Kassir A, Colon S, Glastre C, Tourniaire B, Parchoux B, Martin X, David L. Recurrent nephrotic syndrome after transplantation: early treatment with plasmaphaeresis and cyclophosphamide. Pediatr Nephrol. 1993;7:50-4. (Pubitemid 23045337)
208. Raafat RH, Kalia A, Travis LB, Diven SC. High dose oral cyclosporin therapy for recurrent focal segmental glomerulosclerosis in children. Am J Kidney Dis. 2004;44:50-6. (Pubitemid 38880926)
209. Crosson JT. Focal segmental glomerulosclerosis and renal transplantation. Transpl Proc. 2007;39:737-43.
210. Rodriguez-Ferrero M, Ampuero J, Anaya F. Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis. Transpl Proc. 2009;41:2406-8.
211. Dello Strologo L, Guzzo I, Laurenzi C, Vivarelli M, Parodi A, Barbano G, Camilla R, Scozzola F, Amore A, Ginevri F, Murer L. Use of rituximab in focal glomerulosclerosis relapses after renal transplantation. Transplantation. 2009;88:417-20.
212. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med. 1992;326:1373-9.
213. Euler HH, Schroeder JO, Harten P, Zeuner RA, Gutschmidt HJ. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum. 1994;37:1784-94. (Pubitemid 24371881)
214. Wallace DJ, Goldfinger D, Pepkowitz SH, Fichman M, Metzger AL, Schroeder JO, Euler HH. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J Clin Apher. 1998;13:163-6. (Pubitemid 29029275)
215. Danieli MG, Palmieri C, Salvi A, Refe MC, Strusi AS, Danieli G. Synchronized therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J Clin Apher. 2002;17:72-7. (Pubitemid 34809554)
216. Christian Pagnoux. Plasma exchange for systemic lupus erythematosus. Transfus Apher Sci. 2007;36:187-93.
217. Uthman I, Shamseddine A, Taher A. The role of therapeutic plasma exchange in catastrophic antiphospholipid syndrome. Transfus Apher Sci. 2005;33:11-7. (Pubitemid 40982143)
218. Cervera R, CAPS Registry Project Group. Catastrophic antiphospholipid syndrome (CAPS): update from the 'CAPS Registry'. Lupus. 2010;19:412-8.
219. Doruk Erkan. Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome. Autoimmun Rev. 2006;6:98-103.
220. Martin JN Jr, Files JC, Blake PG, Perry KG Jr, Morrison JC, Norman PH. Postpartum plasma exchange for atypical pre-eclampsia- eclampsia as HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Am J Obstet Gynecol. 1995;172:1107-25.
221. Eser B, Guven M, Unal A, Coskun R, Altuntas F, Sungur M, Serin IS, Sari I, Cetin M. The role of plasma exchange in HELLP syndrome. Clin Appl Thromb Hemost. 2005;11:211-7. (Pubitemid 40548005)
222. Forster JG, Peltonen S, Kaaja R, Lampinen K, Pettila V. Plasma exchange in severe postpartum HELLP syndrome. Acta Anaesthesiol Scand. 2002;46:955-8. (Pubitemid 34953679)
223. Za G, Figini E, Hardonk F, Cordone M, Passamonti U, Bocchino G, Santi F, DeNegri P, Mazzarello GF, Rivabella L. Plasma exchange in a case of HELLP syndrome associated with disseminated intravascular coagulation. Minerva Ginecol. 1991;43:315-7.
224. Hamada S, Takishita Y, Tamura T, Naka O, Higuchi K, Takahashi H. Plasma exchange in a patient with postpartum HELLP syndrome. J Obstet Gynaecol Res. 1996;22:371-4. (Pubitemid 26288335)
225. Cosmai EM, Puzis L, Tsai HM, Lian EC. Thrombocytopenic purpura and cardiomyopathy in pregnancy reversed by combined plasma exchange and infusion. Eur J Haematol. 2002;68:239-42. (Pubitemid 34717826)
226. Del Fante C, Perotti C, Viarengo G, Gallini GS, Tinelli C, Salvaneschi L. Daily plasma-exchange for life-threatening class I HELLP syndrome with prevalent pulmonary involvement. Transfus Apher Sci. 2006;34:7-9. (Pubitemid 43220383)
227. Szucs G, Szamosi S, Aleksza M, Veres K, Soltesz P. Plasmapheresis therapy in systemic sclerosis. Orv Hetil. 2003;144:2213-7.
228. Szekanecz Z, Aleksza M, Antal-Szalmas P, Soltesz P, Veres K, Szanto S, Szabo Z, Vegvari A, Szamosi S, Lakos G, Sipka S, Szegedi G, Varga J, Szucs G. Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follow-up of immunopathological and clinical effects. Clin Rheumatol. 2009;28:347-50.
229. Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C, Farge D, Fligelstone K, Foldvari I, Furst DE, Muller-Ladner U, Seibold J, Silver RM, Takehara K, Toth BG, Tyndall A, Valentini G, van den Hoogen F, Wigley F, Zulian F, Matucci-Cerinic M, EUSTAR Co- Authors. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68:620-8.